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The equine infectious anemia virus (EIAV) long-terminal repeat (LTR) has been identified as highly variable, both in infected
horses and in cell culture. This nucleotide hypervariation is localized to the LTR enhancer region. The EIAV LTR has been
implicated in controlling both the cell tropism and virulence of the virus and it is postulated that the enhancer-region
hypervariation may be responsible for the LTR effects. Our previous studies have demonstrated that the presence of DNA
motifs bound by the ets transcription-factor family member PU.1 are critically important for EIAV expression in equine
macrophages. Here we identify and characterize the EIAV LTR enhancer motifs PEA-2, Lvb, Oct, and CRE, that bind to
fibroblast nuclear extracts. Three of these four motifs, PEA-2, Oct, and CRE, were determined to be important for expression
of the LTR in a fibroblast cell line that supports productive infection of EIAV. These motifs that are important for expression
of the LTR in fibroblasts were found to be interdigitated between the PU.1 sites. We hypothesize that the combination of motif
interdigitation and cell-specific usage of these motifs may be responsible for the observed EIAV LTR enhancer-region
hypervariation. © 2000 Academic Press
w
tINTRODUCTION
Equine infectious anemia virus (EIAV) is a retrovirus
within the subfamily of Lentiviridae. Unlike other mem-
bers of the Lentiviridae, EIAV causes an acute disease
rather than a slow, progressive one. Within several
weeks of infection of a horse, high levels of viremia can
be detected and is accompanied by fever and thrombo-
cytopenia (Sellon, 1993). This initial episode usually re-
solves over several days to weeks. Subsequent viremic
episodes can, but do not always, occur and tend to be
less severe. Eventually, viremia is controlled, with ex-
pression being restricted (Oaks et al., 1998) and cultur-
able infectious virus becoming undetectable; however,
infected horses remain seropositive for life and viral and
proviral sequences remain detectable by PCR (Kim and
Casey, 1994; Langemeier et al., 1996; Maury et al., 1997;
Oaks et al., 1998).
Cell types important for EIAV replication have been
investigated both in vivo and in tissue culture. Through in
situ studies, tissue macrophages have been demon-
strated to be infected by EIAV during both acute and
persistent infection in vivo (McGuire et al., 1971; Sellon et
al., 1992, 1996). Until recently, it was believed that mac-
rophages were the only cell type infected in vivo; how-
ever, Oaks et al. (1999) have shown that endothelial cells
1 To whom correspondence and reprint requests should be ad-
ressed at University of Iowa, Department of Microbiology, 3-615 Bo-
en Science Building, Iowa City, IA 52242. E-mail: wendy-
aury@uiowa.edu.
267are infected during acute, virulent infection. The recent
recognition that the endothelium is infected in vivo has
suggested the possibility that other as-yet unidentified
cell types may also be important during the acute infec-
tion and/or persistence of EIAV. In tissue culture, a num-
ber of cells and cell lines have been used to study EIAV
replication. EIAV infection of equine macrophages, endo-
thelial cells, fibroblasts, and canine and feline fibroblast
cell lines has been well documented (Kono et al., 1967;
Klevjer-Anderson et al., 1979; Maury et al., 1998).
Strains of EIAV exhibit differing cell tropism. Some
strains replicate exclusively in macrophages, whereas
other strains replicate exclusively or to higher levels in
fibroblasts, fibroblast cell lines, or endothelial cells (Car-
penter and Chesebro, 1989; Perry et al., 1992; Maury et
al., 1998). In vitro macrophage tropism tends to correlate
with in vivo virulence, whereas fibroblast-tropic strains
have been found to be poorly virulent or avirulent (Car-
penter and Chesebro, 1989; Perry et al., 1992). Attempts
to map the viral determinants of cell tropism and/or
virulence indicate that the determinants can be found in
the 39 end of the genome (Perry et al., 1992; Payne et al.,
1994; Madden and Shih, 1996; Cook et al., 1998; Payne et
al., 1998; Lichtenstein et al., 1999). Envelope, rev, and
LTR sequences may be important for virulence (Cook et
al., 1998; Payne et al., 1998; Lichtenstein et al., 1999),
hereas only the env and LTR may be involved in cell
ropism (Perry et al., 1992; Payne et al., 1994; Maury et al.,1997). The role of both the env and LTR sequences in
controlling EIAV cell tropism stands in contrast to HIV, in
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268 MAURY ET AL.which the LTR does not appear to play a role in cell
tropism (Pomerantz et al., 1991).
Evidence suggests that the enhancer region is respon-
sible for the effect of the LTR on cell tropism and viru-
lence (Carpenter et al., 1991; Maury, 1994; Madden and
Shih, 1996; Maury et al., 1997). The EIAV enhancer region
derived from either tissue culture (Carpenter et al., 1991;
erse et al., 1993) and horses (Payne et al., 1994; Maury
t al., 1997) is surprisingly hypervariable. A study of
even EIAV-infected horses demonstrated that 45% of
ucleotide positions within the enhancer region were
ariable, whereas only 5% of the nucleotide positions
ere variable within the remainder of the LTR (Maury et
l., 1997). The localized enhancer-region variation can be
ound as deletions, insertions, and point mutations and
he changes frequently result in transcription-factor bind-
ng motif alterations. In this same study, LTR enhancer
equences isolated from horses during acute EIAV infec-
ion differed from the enhancer sequences found in long-
erm seropositive horses, providing evidence that the
nhancer region may play an important role in virulence.
he LTR sequences from three different acutely ill horses
ere similar and all contained three binding sites for the
ts family transcription factor PU.1, which has been
hown to be important for expression of the EIAV LTR in
quine macrophages (Maury, 1994). LTR sequences from
ong-term seropositive horses were found to be more
ariable, had frequently lost one or more of the PU.1
ites, and were more closely related to LTR sequences
ound in fibroblast-passaged virus (Maury et al., 1997).
A next step in understanding EIAV cell tropism is to
map LTR and envelope sequences responsible for cell
tropism. Here we use a highly infectable and transfect-
able fibroblast cell line, Cf2Th cells, as a model for
haracterizing LTR expression in nonmonocytic cells. We
ound that the transcription-factor motifs required for
xpression in fibroblasts differed from those motifs pre-
iously identified to be important for EIAV LTR expression
n macrophages (Carvalho and Derse, 1993a; Maury,
994). This indicated that the repertoire of transcription
actors used to stimulate EIAV expression are cell spe-
ific. The cell-specific usage of transcription factors may
xplain the involvement of LTR sequences in cell tropism
etermination and, perhaps, virulence. Furthermore, the
ell specificity of the transcription factors used for EIAV
TR expression may serve as a selective pressure that
esults in LTR enhancer-region hypervariation.
RESULTS
dentification of sequences within the EIAV LTR U3
hat enhance transcriptional activity in fibroblasts
The length of the EIAV LTR is variable both in vitro
Carpenter et al., 1991; Derse et al., 1993; Maury, 1994)
nd in vivo (Payne et al., 1994; Maury et al., 1997) as a
esult of nucleotide insertions and deletions that occur
C
sithin the enhancer region; however, the most common
TR length is 323 bp. Thus, for this study we used a
23-bp LTR from a healthy, seropositive horse from Mon-
ana (Maury et al., 1997). This LTR is identical to that
reviously described for the MA-1 strain of virus that is
ibroblast-tropic (Carpenter and Chesebro, 1989). Fur-
hermore, this LTR is similar, but not identical, to the LTR
ound in the macrophage-tropic strain of virus Th.1 (Car-
enter and Chesebro, 1989) that we previously used to
efine transcription-factor motifs important for expres-
ion of EIAV in equine macrophages (Maury, 1994).
To initially define sequences within the EIAV LTR im-
ortant for LTR expression in nonmonocytic cells, a se-
ies of LTR U3 deletions were made, introduced into the
eporter plasmid pCATbasic, and were transiently trans-
ected into the productively infectable canine fibroblast
ell line Cf2Th (Fig. 1A). No mutations were made in the
ATA box or the R-U5 sequences. Transient transfections
ere performed in the absence (basal) and presence
Tat-transactivated) of the RSV/EIAV tat plasmid (Ste-
hens et al., 1990). EIAV Tat dramatically upregulates
asal levels of LTR expression (Dorn et al., 1990) by
nteracting with the TAR stem-loop structure formed from
ascently made viral RNA similar to that of HIV Tat for the
IV LTR (Kao et al., 1987; Selby et al., 1989; Roy et al.,
991). To determine background levels of CAT activity,
arallel transfections of the parental pCATbasic plasmid
ith and without the RSV/EIAV tat plasmid were per-
ormed.
DSX3 was deleted from the XhoI site at the 59 end of
he U3 to position 252 relative to the start of transcrip-
ion. DSX3 also contained a three-nucleotide mutation
hat eliminated the transcription-factor site at position
44 to 236, known to bind to the ets family member
U.1. Thus, the DSX3 construct was designed to elimi-
ate any upstream enhancer sequences. Expression
rom DSX3 was used in this study as representative of
he level of expression resulting from the interaction of
he basal transcription machinery with the TATA box in
he absence of any enhancer motifs (Fig. 1B). The levels
f both basal and Tat-transactivated expression from
SX3 were low and not significantly different from those
ound with pCATbasic. The 59 del/CAT construct deleted
7 nucleotides from 299 to 252, but left the PU.1 site at
44 to 236 intact. This construct had baseline basal
ctivity and Tat-transactivated expression elevated only
bout twofold over the pCATbasic levels. Findings from
hese two constructs suggested that the motifs important
or stimulating both basal and Tat-transactivated EIAV
xpression in these fibroblastic cells could be localized
o the 47-bp region that was deleted in 59 del/CAT.
Two smaller, more 39 deletion mutations also were
ade that deleted either 33 nucleotides from 285 to 252
39 del/CAT) or 14 nucleotides from 266 to 252 (157/
AT). Basal levels of expression were approximately
evenfold lower than wild-type LTR/CAT with both of
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269EIAV EXPRESSION IN NONMONOCYTIC CELLSthese constructs; however, EIAV Tat was able to trans-
activate the expression from these plasmids by 30-fold or
more. Transient transfections of these same constructs
into another fibroblastic cell line FEA, permissive for
EIAV replication, resulted in similar findings, indicating
that this finding was not specific for Cf2Th cells (data not
shown). In total, these data suggested that nucleotides
between 266 and 252 were important for basal levels of
LTR expression and an overlapping region between 299
and 252 influenced the ability of Tat to transactivate the
TR.
dentification of transcription-factor motifs that
nteract with fibroblast nuclear extracts and
haracterization of the proteins that bind to them
To identify transcription-factor binding sites within this
FIG. 1. Identification of EIAV enhancer region by analysis of LTR/CA
Montana LTR that enhanced transcription in Cf2Th cells. The deletion
represent deleted nucleotides. Lowercase letters denote introduced nu
was measured in the absence and presence of EIAV Tat. The positio
Percentage acetylation values represent the mean values with the stan
shown for each construct as fold Tat transactivation. All experiments w0-nucleotide region, a series of overlapping double-
tranded oligonucleotides (Fig. 2) were synthesized and
n
csed in electrophoretic mobility shift assays (EMSAs),
sing nuclear extracts (NE) from the Cf2Th cells. Speci-
icity of the retarded bands in this study was determined
y the ability of an unlabeled self oligonucleotide to
ompete for binding and the inability of the same con-
entration of a heterologous oligonucleotide of similar
ength to compete for the binding. Specific interactions
etween the labeled oligonucleotides and the fibroblast
E were observed as retarded bands in EMSAs using
ive of the oligonucleotides: 105, 116, 129, 142, and 153
Fig. 3A). Similar EMSA studies have been performed in
he equine dermal fibroblasts (ED cells) and in FEA with
imilar shifting results (data not shown), indicating that
he same pattern of NE binding is found in a number of
ibroblastic cells that support EIAV replication.
A series of mutations generated in each of the oligo-
tructs made through deletion mutagenesis. (A) The sequence of the
that were studied are shown below the wild-type sequence. Dashes
mutations. (B) CAT activity of wild-type or deleted LTR/CAT constructs
e deleted nucleotides relative to the start of transcription is shown.
rror. The increase in LTR activity resulting from the presence of Tat is
rformed in triplicate at least three independent times.T cons
mutants
cleotide
n of thucleotides that exhibited specific binding were used in
ompetition assays to identify the nucleotides within
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270 MAURY ET AL.each oligonucleotide that were responsible for NE bind-
ing (data not shown). From these studies, the transcrip-
tion-factor binding motif present within each of the five
oligonucleotides was identified. A comparison of the
EIAV LTR binding sites identified through these studies
and previously published consensus sequences for each
transcription-factor motif is shown in Fig. 3B. Oligonucle-
otide 105 contained a PEA-2 site (also called core bind-
ing factor [CBF] or polyomavirus enhancer-binding pro-
tein 2 [PEBP2]). This transcription-factor binding motif
was originally identified in the polyoma enhancer and
has subsequently been identified in a number of genes
expressed in hematopoetic cells (Wang and Speck, 1992;
Satake et al., 1995). The AML family of transcription
factors has been shown to bind to the PEA-2 site in other
promoter/enhancer regions (Wang and Speck, 1992; Bae
et al., 1993; Nuchprayoon et al., 1994). Oligonucleotide
116 contained a motif that was identical to the Lvb site
previously characterized in the Moloney murine leuke-
mia virus (MMLV) LTR (Boral et al., 1989; Wang and
Speck, 1992). Oligonucleotide 129 contained an octamer
site (Scheidereit et al., 1988). Oligonucleotides 142 and
153 overlapped the same cAMP response element (CRE)
(Roesler et al., 1988). The PU.1-binding motifs present
within oligonucleotides 136 and 163 did not interact with
the Cf2Th NE. A third, 59 PU.1 motif was present in
oligonucleotide 129 along with an octamer motif. By
mutant oligonucleotide competition studies, Cf2Th NE
was found to interact with the octamer motif, but not with
the PU.1 motif (data not shown). Thus, our EMSA studies
suggested that the transcription-factor usage in fibro-
blasts was completely different from that found in mac-
rophages.
FIG. 2. The EIAV LTR enhancer-region oligonucleotides used in EM
EIAV-seropositive mare from Montana. (B) The sense strand of overlapp
containing mutations, the mutations are shown in bold lowercase lette
1 or 2.Supershifting studies were performed to identify pro-
teins present in the Cf2Th NE that interacted with the
o
tbound sites (Fig. 4). While antibodies and antisera
against canine transcription factors are not available, the
ubiquitous nature of transcription factors allowed us to
use antibodies against mouse and human factors.
The specific binding observed with oligonucleotide
105 that contained a consensus PEA-2 site was super-
shifted with antisera to the transcription factors AML 1
and AML 2, but not AML 3 (Fig. 4A). Chromosomal
recombinations involving the AML-1 gene and expres-
sion of AML proteins in hematopoetic precursors and in
osteoblasts, have been studied (Satake et al., 1995; Ban-
erjee et al., 1996); however, the importance of AML pro-
teins in fibroblasts is not clear.
The specific band shifted by oligonucleotide 129 and
Cf2Th NE was not supershifted, but was eliminated by
ntisera to Oct-1, a ubiquitous transcription factor (Fig.
B) (Chang et al., 1991). Elimination of Oct-1 binding by
his antisera has previously been reported (Skala et al.,
998) and suggested that competition between the anti-
era and the DNA for Oct-1 was occurring.
Finally, antisera were used to identify the transcription
actors responsible for the band retarded by oligonucle-
tides 142 and 153 (Fig. 4C). This site within the EIAV LTR
ad previously been characterized as an AP-1 site,
ased on sequence homology (Carpenter et al., 1991;
arvalho and Derse, 1993b; Carvalho et al., 1993; Derse
t al., 1993; Lichtenstein et al., 1996; Cook et al., 1998). A
eries of anti-Jun and anti-Fos antibodies were used as
ell as numerous antibodies to cAMP responsive ele-
ent (CRE) binding proteins. Figure 4C demonstrates the
bility of two different antiactivating transcription factor-1
ATF-1) antibodies to supershift the retarded complex
dies. (A) The enhancer region of the wild-type LTR obtained from an
thetic oligonucleotides used in the EMSA studies. In oligonucleotides
ability of Cf2Th NE to interact with each oligonucleotide is noted by aSA stu
ing synbserved with oligonucleotide 142. No other antibodies
ested affected the shifting pattern, indicating that ATF-1
were o
271EIAV EXPRESSION IN NONMONOCYTIC CELLSwas responsible for the band retardation and suggested
that this site is a CRE site, not an AP-1 site.
The Lvb site within oligonucleotide 116 demonstrated
weak, but specific binding to Cf2Th cell NE. An Lvb site
in MMLV LTR and in the T-cell receptor stimulated tran-
scription through interactions with the transcription fac-
tors Ets 1 and 2 (Sun et al., 1995). Antisera to several ets
family members, including anti-Ets 1 and 2 antisera as
FIG. 3. EMSA studies on the Montana LTR enhancer region with C
oligonucleotides 105, 116, 129, 142, and 153. The sequences of oligonu
2. For each 32P-labeled probe, three lanes are shown. Competitor lanes
oligonucleotide. The second lane in each series demonstrates the abil
each series demonstrates the specificity of the probe/NE interaction by
were performed as described under Materials and Methods. (B) A co
consensus motif that had been previously reported. Consensus motifs
consensus motif and the EIAV motif are shown in lowercase letters.well as a series of other ets family members, were
unable to supershift the oligonucleotide 116 complexsuggesting that these proteins are not responsible for
the specific binding observed to oligonucleotide 116
(data not shown).
Identification of U3 sequences important for basal
and Tat-transactivated expression in fibroblasts
Through the EMSA studies outlined earlier, four tran-
. (A) Specifically retarded bands were observed in the EMSAs using
s used as probes or as competitor oligonucleotides are shown in Fig.
ed no competitor or 200 ng of unlabeled, blunt-ended, double-stranded
nlabeled self oligonucleotide to compete for binding. The third lane in
sence of excess amounts of nonhomologous oligonucleotide. EMSAs
on of the transcription-factor motifs found in the Montana LTR and a
btained from the references noted. Nucleotides that differ between thef2Th NE
cleotide
contain
ity of u
the pre
mparisscription-factor motifs were found to interact with fibro-
blast NE: PEA-2, Lvb, Oct, and CRE. To determine
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272 MAURY ET AL.whether these motifs were important for regulating LTR
expression in fibroblasts, point mutations were made in
the LTR/CAT construct followed by CAT assays. Point
mutations were initially introduced into the PEA-2, Oct,
and CRE sites independently (Fig. 5). The mutation intro-
duced at each site eliminated Cf2Th NE binding to the
ite in EMSAs (data not shown). Mutations in any one of
he three sites did not significantly decrease either basal
r Tat-transactivated levels of expression. Surprisingly,
utations in either the PEA-2 or Oct site enhanced Tat
ransactivation.
Consequently, the introduction of multiple mutations
ithin the LTR/CAT construct were made and assayed.
ual mutations in the adjacent PEA-2 and Lvb sites
mP/mL) resulted in wild-type levels of both basal and
at-transactivated activity (data not shown). Alterations at
he PEA-2, Lvb, and Oct sites (mP/mL/mO) resulted in a
FIG. 4. Ability of antisera to supershift bands retarded in an EMSA us
in Fig. 2. Antisera used in each lane are as noted. (A) Ability of anti-AM
105. (B) Ability of anti-Oct-1 antisera to disrupt the binding of oligonucleo
o oligonucleotide 129 appeared to be specific, as this antisera did not
and 142 (data not shown). (C) Ability of two different anti-ATF-1 antisera
studies and protocol of the experiments are described under Material
Arrow in panel B highlights the original gelshifted band.0% drop in basal levels of LTR activity, whereas combi-
atorial mutations of either the PEA-2, Lvb, and CRE
m
umP/mL/mC) or Oct and CRE (mO/mC) resulted in an
pproximate 90% decrease in basal activity and a CAT
alue similar to that found with the empty CAT vector
lone (pCATbasic) in the previously described deletion
tudies. Thus, unlike the deletion analysis experiments
escribed earlier, these basal expression studies using
oint mutations indicated that no specific individual site
as critical for expression. Instead, these findings sug-
ested that functional complementarity between the dif-
erent sites existed. Elimination of one site was compen-
ated by the presence of the other sites within the LTR,
hereas alterations of two or three sites decreased
asal levels of expression.
In contrast to the decrease in basal levels, the effect of
hese multiple-site mutations on Tat-transactivated ex-
ression was modest; an approximate 50% drop in fold
ctivation was observed with the mO/mC and mP/
Th NE. The sequences of oligonucleotides used as probes are shown
d anti-AML-2 antisera to supershift bands retarded by oligonucleotide
9 and Cf2Th NE. The ability of the anti-Oct-1 antisera to disrupt binding
re with the binding of Cf2Th NE to other oligonucleotides such as 116
ershift bands retarded by oligonucleotide 142. Antisera used in these
ethods. Arrows in panels A and C highlight the supershifted bands.ing Cf2
L-1 an
tide 12
interfe
to supL/mC mutants and the fold Tat transactivation was
naffected by the mP/mL/mO mutation. These findings
or each
prese
mes.
273EIAV EXPRESSION IN NONMONOCYTIC CELLSfurther indicated that functional complementarity existed
between the different transcription-factor sites within the
enhancer region, especially in the presence of EIAV Tat.
A final set of point mutations was made that altered
the PEA-2, Oct, and CRE sites (mP/mO/mC). In this mu-
tant, the Lvb site remained intact. Basal levels of expres-
sion were again decreased to levels found for the empty
CAT vector. Tat-transactivated expression was de-
creased to levels found with the deletion construct 59
del/CAT. Thus, point mutations of the PEA-2, Oct, and
CRE sites resulted in basal and Tat-transactivated levels
of expression similar to levels found with the minimal
promoter alone, indicating that in Cf2Th cells, these three
sites within the enhancer control expression in fibro-
blasts.
DISCUSSION
FIG. 5. CAT activity of EIAV LTR/CAT constructs containing point m
mutants are shown. Transcription-factor motifs identified in this and ot
nucleotides. (B) CAT activity of LTR/CAT constructs mutated in the PEA
absence and presence of EIAV Tat. Sites that are mutated are noted f
with the standard error. The increase in LTR activity resulting from the
experiments were performed in triplicate at least three independent tiDuring this study, we identified motifs within the EIAV
LTR enhancer that regulated expression in a nonmono-cytic cell. Our initial LTR-deletion studies identified a
47-bp region that strongly enhanced expression of the
LTR. EMSAs identified four sites within the 47-bp region
that specifically bound to proteins from fibroblast NEs:
PEA-2, Lvb, Oct, and CRE. This set of transcription-factor
motifs differed from those bound by macrophage NE that
contains the macrophage and B cell-specific transcrip-
tion factor PU.1. Thus, different repertoires of transcrip-
tion-factor binding motifs are needed for expression of
the LTR in macrophages versus fibroblasts. Interestingly,
within the LTR enhancer region, the PEA-2, Lvb, Oct, and
CRE sites are interdigitated between the three PU.1 bind-
ing sites (Fig. 6). The cell-specific use of these interdig-
itated transcription-factor motifs may explain the EIAV
LTR enhancer-region hypervariation found both in vitro
and in vivo. The in vivo relevance of the transcription-
factor repertoire used by fibroblasts is highlighted by the
s. (A) The sequences of the Montana enhancer sequence and point
dies are noted on the wild-type sequence. Dashes represent deleted
, Oct, and/or CRE sites are shown. CAT activity was measured in the
construct. Percentage acetylation values represent the mean values
nce of Tat is shown for each construct as fold Tat transactivation. Allutation
her stu
-2, Lvbfact that these motifs are found in a naturally occurring
EIAV isolate from Montana.
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274 MAURY ET AL.Two of these sites, PEA-2 and CRE, had been identi-
fied as transcription-factor motifs in the EIAV LTR in a
previous study using a smaller EIAV LTR obtained from
the Malmquist strain of EIAV (Carvalho and Derse, 1993b;
Carvalho et al., 1993); however, the CRE site had been
dentified as an AP-1 site (Carvalho and Derse, 1993b). In
ddition, another binding site 39 to the CRE site was
dentified in the Malmquist strain through point muta-
ions of the overlapping PU.1 site. This region of the
nhancer corresponded to oligonucleotide 163 in our
tudies. We did not observe any binding of the enhancer
o this region; however, in earlier studies with macro-
hage NE, this region did bind to the macrophage-spe-
ific transcription factor PU.1 (Maury, 1994).
Supershifting studies were used to identify the fibro-
last proteins that interacted with the different motifs.
wo proteins from the AML transcription-factor family,
ML 1 and 2, bound to the PEA-2 site, but no binding of
ML 3 was detected using anti-AML 3 antisera. In con-
unction with the non-DNA-binding subunit CBF-b (Wang
et al., 1996), multiply spliced forms of the AML proteins
are primarily, but not exclusively, hematopoetic transcrip-
tion factors that regulate expression of T, B, and myeloid-
specific genes (Bae et al., 1993; Suzow and Friedman,
1993; Nuchprayoon et al., 1994; Satake et al., 1995). It is
interesting that we, as well as others (Carvalho and
Derse, 1993b), have detected EIAV LTR PEA-2 binding
activity in fibroblast NE; however, we were not able to
detect PEA-2 binding activity in NE from mature equine
macrophages (Maury, 1994).
The Lvb site demonstrated specific interactions with
Cf2Th NEs, but did not appear to be important for EIAV
TR transcriptional activity. The Lvb site is located down-
tream from and adjacent to the PEA-2 site within the
IAV LTR. A similar juxtaposition of these sites is found
FIG. 6. A model of the cell-specific use of transcription-factor motifs i
of EIAV LTR. Transcription-factor motifs, PU.1 sites, bound by primary
above the line. Transcription-factor motifs bound by Cf2Th NE are sho
LTR in Cf2Th cells include the PEA-2, Oct, and CRE sites. These sites
these sites may explain the LTR enhancer-region nucleotide hypervarn the MMLV LTR (Sun et al., 1995), the T-cell receptor
Prosser et al., 1992; Sun et al., 1995), and the immuno-lobulin heavy-chain enhancer (Erman et al., 1998). In
hese other enhancers, it has been demonstrated that
he transcription factors Ets 1 and 2 can bind to the Lvb
ite and that the Ets proteins interact with AML proteins,
hich are bound to the PEA-2 site (Wotton et al., 1994).
urthermore, these interactions have been demonstrated
o be important for expression of these genes and are
nhanced by cellular activation with phorbol myristate
cetate (PMA) (Prosser et al., 1992; Sun et al., 1995). In
ontrast, the protein(s) in Cf2Th NE that bound to the
IAV Lvb site did not appear to be Ets proteins, since
nti-Ets antisera did not supershift the complex. In addi-
ion, no interaction of the proteins bound to the PEA-2
nd Lvb sites in the EIAV LTR could be discerned by
MSA studies (data not shown). Furthermore, from our
xpression studies, the Lvb site did not appear to be
mportant for EIAV LTR expression. Nevertheless, an Lvb
ite has been found in a number of isolates of EIAV and
ay be important for EIAV expression in other cell types,
uch as endothelial cells (Maury et al., 1998), or in acti-
ated cells.
From our supershifting studies, the Oct site appeared
o be occupied by the ubiquitious transcription factor
ct-1 in fibroblasts. We have also detected octamer-site
inding activity in equine macrophage NE; however, an
ctamer site has yet to be identified within a macroph-
ge-tropic strain of EIAV (Maury, unpublished data). Fi-
ally, the CRE site, previously characterized as an AP-1
ite, was exclusively occupied by ATF-1, thus defining
his site as a CRE site.
Earlier studies investigating the hypervariation asso-
iated with the LTR have speculated that several CAAT
otifs, frequently present within the EIAV enhancer, may
e important for expression of the LTR (Payne et al., 1994;
Lichtenstein et al., 1996; Cook et al., 1998). A CAAT motif
IAV LTR. The thick black line represents the enhancer/promoter region
macrophage NE as determined previously (Maury, 1994) are shown
w the line. Transcription-factor motifs important for expression of the
erdigitated and overlap with the PU.1 sites. The cell-specific usage of
bserved in vivo and in vitro.n the E
equine
wn belo
are intis located at 292 relative to the start of transcription
within the Montana LTR. An additional CAAT motif is
a
a
(
F
C
(
a
t
t
275EIAV EXPRESSION IN NONMONOCYTIC CELLSfrequently found at approximately 272 in many macroph-
age-tropic LTR sequences. Our studies in macrophages
(Maury, 1994) and in fibroblasts have not provided any
evidence that these sequences bind to either NE or are
important for EIAV LTR expression.
Any one of the PEA-2, Oct, or CRE sites could be
eliminated from the enhancer region without a deleteri-
ous effect on LTR activity; however, alteration of any two
sites decreased basal levels of expression by 60–90%.
Mutations that included the CRE site resulted in the
greatest loss of expression. Whether the CRE site was
relatively more important than the other sites, strictly
because of its proximal position to the TATA box, is not
known.
The presence of any one of the three sites permitted
EIAV Tat to transactivate the LTR, despite the fact that
basal levels of expression from two of these multiply
mutated constructs (mO/mC and mP/mL/mC) were sim-
ilar to values obtained with DSX3, the minimal promoter
construct. Thus, an interesting paradox involving EIAV
Tat transactivation was found: basal levels of some of the
multiple-site mutation constructs were similar and yet
the ability of Tat to transactivate these constructs was
variable. For instance, the basal level of CAT activity of
mP/mL/mC was identical to mP/mO/mC and yet the
ability of Tat to transactivate these constructs was differ-
ent (25- versus 6.3-fold). Similar effects of mutagenesis of
HIV transcription-factor motifs on HIV Tat transactivation
have been noted in that system (Rosen et al., 1985).
Several explanations are possible. First, it is possible
that modest changes in basal activity that are sufficient
to allow Tat transactivation cannot be detected by our
CAT assay. Second, a recent study has suggested that
EIAV Tat may transactivate through DNA interactions in
the enhancer region in a manner similar to that of visna,
rather than through TAR RNA/Tat interactions (Willbold et
al., 1998). Studies from our lab as well as others indicate
that Tat does not require these DNA sequences for
transactivation, but does require the presence of TAR
sequences (Derse et al., 1990, 1991; Dorn et al., 1990;
Carroll et al., 1991, 1992; Carvalho and Derse, 1991;
Maury and Hines, in press). Furthermore, Bieniasz et al.
(1999) have recently demonstrated EIAV Tat/TAR RNA
interactions. Therefore, this explanation remains unlikely.
A third possible explanation is that the presence of a
single transcription-factor site increases the number of
stalled transcripts made, but not full-length messages.
Consequently, in the absence of Tat, basal activity does
not increase; however, the presence of Tat alleviates this
block, allowing high levels of Tat transactivation. More
detailed biochemical analyses of the transcription prod-
ucts will be required to determine whether synthesis of
larger numbers of stalled transcripts occur in the pres-
ence of a single enhancer site than in the presence of
the minimal promoter alone.MATERIALS AND METHODS
Electrophoretic mobility shift assays (EMSAs) and su-
pershifting assays. EMSAs were performed as previously
described (Maury, 1994). Briefly, nuclear extracts (NE)
from the fibroblast cell line Cf2Th, that supports replica-
tion of EIAV, were obtained following the procedure de-
scribed by Dignam et al. (1983). Double-stranded oligo-
nucleotides approximately 24 nucleotides long were syn-
thesized, based on the sequence of the LTR from an
EIAV-seropositive, healthy horse from Montana as the
template. These oligonucleotides were labeled with 32P-
dNTPs and incubated with approximately 10 mg of NE in
a 20-ml volume for 30 min at room temperature, in the
presence of binding buffer containing 90 mM KCl, 1 mM
Mg2Cl, and 4 mg poly (dI-dC) (Sigma, St. Louis, MO).
Blunt-ended, unlabeled 400-fold excess oligonucleotides
(200 mg) were used as cold competitors to determine the
specificity of binding of NE. EMSAs using oligonucleo-
tides 105 and 116 were run on a 5% acrylamide gel in 1X
Tris–glycine buffer. EMSAs using all other oligonucleo-
tides were run on a 5% acrylamide gel in 1X TBE buffer.
All gels were fixed in 50% methanol and 10% acetic acid
for 15 min and dried. Gel-shifted bands were visualized
by autoradiography.
Commercially available polyclonal and monoclonal an-
tibodies (mAb) tested for their ability to interact with the
protein–oligonucleotide complexes were used at a final
concentration of 100 ng/ml. These antibodies included
nti-Oct-1 (Santa Cruz 232x), anti-ATF-1 (Santa Cruz 270x
nd 243x), anti-CREB-1 (Santa Cruz 186x), anti-ATF-2
Santa Cruz 187), anti-CREB-2 (Santa Cruz 200x), anti-c-
os (Santa Cruz 447x, 253x, and 52x), anti-FosB (Santa
ruz 48x), anti-Jun (Santa Cruz 44x and 45x), anti-PU.1
Santa Cruz 352x), anti-Ets 1 and 2 (Santa Cruz 112x), and
nti-PEA-3 (Santa Cruz 113x). Neat rabbit polyclonal an-
isera provided by other research laboratories were
ested for supershifting activity at a concentration of 1
ml/reaction or as noted in figure 4. Anti-AML antisera
was kindly provided by Dr. S. Heibert (Vanderbilt Univ.
School of Medicine). In assays in which antisera and
antibodies were tested, nuclear extracts were preincu-
bated with antibodies for 30 min at room temperature in
binding buffer prior to the 30-min incubation with probe.
Construction of LTR/CAT mutations. The parental LTR
used for these studies was from a PCR-amplified LTR
obtained from a seropositive, healthy mare from Mon-
tana (Maury et al., 1997). Oligonucleotides for amplifica-
tion of the LTR were designed to introduce a 59 XhoI site
and a 39 XbaI site into the LTR, using the primers Xho
7606 (ggttttctcgaggggttttataaatg) and Xba 323C9 (tcta-
gagtaggatctcgaaca). An XhoI site was introduced into the
multiple-cloning site of pCATBasic and the LTR was
cloned into the reporter gene plasmid pCATbasic.All mutations except the Oct mutation were introduced
into the wild-type LTR by PCR, using either a sense or
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Depending on whether the mutation-containing primer
was sense (59) or antisense (39), either Xho 7606 or Xba
323C9 primers were used as the complementary primer
during PCR mutagenesis. To facilitate subsequent sub-
cloning steps, mutations in the PEA-2 site were always
designed to contain an AvrII site and mutations in the
RE site always contained an SpeI site. The PCR prod-
cts were cloned into a TA cloning vector and sequenced
t the Iowa State University sequencing facility. Clones
ontaining the appropriate sequence were subcloned
nto the pCATbasic vector. The Oct mutation was ob-
ained from a RT-PCR amplification of the RNA from a
h.1 infection of primary equine macrophages.
Transfections, b-galactosidase assays, and LTR/CAT
ssays. DNAs were transfected into 2 3 105 Cf2Th cells
in six-well trays using the calcium phosphate transfec-
tion procedure (Graham and van der Eb, 1973). Five
micrograms of LTR/CAT plasmid were used for each
transfection and 3 mg of b-gal/pSFF (Maury et al., 1994)
ere added to allow transfection normalization. In trans-
ections in which the effect of EIAV Tat was investigated,
mg of RSV/Etat (Stephens et al., 1990) were cotrans-
ected. Transfected cells were treated with 15% glycerol
or 2 min 4–6 h posttransfection and fresh media was
dded for the remainder of the transfection period. At
5–48 h posttransfection, cells were freeze-thawed five
imes to generate the cell lysates.
b-Gal activity was determined for each lysate to nor-
malize for transfection efficiency. A standard curve using
purified b-galactosidase (Promega, Madison, WI) was
un concurrently to allow adjustment for interexperiment
ariation. Briefly, 30 ml of lysate was mixed with 150 ml of
Z buffer, pH 7.0 (60 mM Na2HPO4, 40 mM NaH2PO4, 10
M KCl, 1 mM MgSO4, and 50 mM 2-ME) and 35 ml of
NPG (4 mg/ml) for approximately 2 h at 37°C. To stop
he reaction, 300 mM NaCO3 was added. OD was read at
414 nm.
CAT assays were performed as previously described
(Maury et al., 1994). Cell lysates were incubated with
14C-chloramphenicol and acetyl CoA as described by
orman et al. (1982). A time course was performed for
lysates to identify the optimal assay time for the LTR/CAT
plasmids alone and in the presence of EIAV Tat. To
ensure that all assays were performed in the linear range
of the CAT assay, lysates that gave greater than 35%
acetylation of the chloramphenicol substrate were rean-
alyzed using either a shorter time frame or less lysate.
Both acetylated and unacetylated 14C-chloramphenicol
ere separated by thin-layer chromatography, using
odak silicone thin-layer sheets (Cat. No. 136-7566) in a
9:1 ratio of chloroform and methanol, and the acetyla-
ion pattern was identified by autoradiography. Acety-
ated and unacetylated chloramphenicol spots were cut
14ut from the thin-layer sheets and the quantity of C in
ach spot was determined by scintillation counting. Themount of CAT activity was expressed as the percentage
cetylation/milliunits of b-gal activity/h. The fold activa-
tion in the presence of Tat was determined by dividing
the rate of acetylation in the presence of Tat by the rate
of acetylation in the absence of Tat. Both the absolute
level of Tat transactivation and the fold increase resulting
from the presence of Tat are reported here; however,
because the absolute level of Tat transactivation was
determined by the basal level of LTR activity, the fold
level of Tat transactivation was used for comparisons
during these studies.
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